Rock Springs Capital Management’s Seres Therapeutics MCRB Stock Holding History

Rock Springs Capital Management’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-11,000	Closed	-$1.67M	–	141
2018 Q3	$1.67M	Hold	11,000	–	–	0.06%	136
2018 Q2	$1.89M	Hold	11,000	–	–	0.07%	134
2018 Q1	$1.61M	Hold	11,000	–	–	0.07%	138
2017 Q4	$2.23M	Hold	11,000	–	–	0.1%	129
2017 Q3	$3.53M	Hold	11,000	–	–	0.16%	115
2017 Q2	$2.49M	Hold	11,000	–	–	0.13%	125
2017 Q1	$2.48M	Hold	11,000	–	–	0.14%	117
2016 Q4	$2.18M	Hold	11,000	–	–	0.15%	111
2016 Q3	$2.7M	Sell	11,000 -2,100	-16%	-$737K	0.17%	112
2016 Q2	$7.61M	Hold	13,100	–	–	0.56%	53
2016 Q1	$6.96M	Buy	13,100 +830	+7%	+$433K	0.58%	55
2015 Q4	$8.61M	Buy	12,270 +3,270	+36%	+$2.15M	0.65%	54
2015 Q3	$5.33M	Sell	9,000 -1,361	-13%	-$1.11M	0.43%	75
2015 Q2	$8.6M	Buy	+10,361	New	+$9.04M	0.63%	56

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Rock Springs Capital Management's MCRB Position: Q4 2018 in Review

Rock Springs Capital Management sold out of Seres Therapeutics (MCRB) in Q4 2018, closing a stake of 11,000 shares — an estimated $1.67M sold.

Rock Springs Capital Management first reported a position in MCRB in Q2 2015 and held it in 14 quarters. The position peaked at $8.61M in Q4 2015. 70 funds tracked by Wall St. Rank hold MCRB as of Q4 2018.

Rock Springs Capital Management reported no remaining Seres Therapeutics position as of Q4 2018 after selling out during the quarter.
Rock Springs Capital Management sold 11,000 Seres Therapeutics shares in Q4 2018, an estimated $1.67M.
Rock Springs Capital Management first reported a position in Seres Therapeutics in Q2 2015 and held it in 14 quarters.
Rock Springs Capital Management's Seres Therapeutics position peaked at $8.61M in Q4 2015.
70 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2018.

Based on Rock Springs Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.